Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Enasidenib mesylate | 1650550-25-6 | 99.7% | 569.48 | 5 MG
Supplier: Medchemexpress LLC 5MGHY18690A
Enasidenib mesylate is a first-in-class, oral, potent, reversible, and selective inhibitor of the IDH2 mutant enzymes. It reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells, inducing differentiation and impairing self-renewal of IDH2-mutant leukemia cells. In vivo studies demonstrate that treatment with enasidenib significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model by remodeling the epigenetic state and reducing 2-hydroxyglutarate (2-HG) levels, consistent with on-target inhibition.
- Novel approach to treatment
- Convenient oral administration
- Potent, reversible, and selective inhibitor
- Induces differentiation of leukemic cells
- Improves survival in AML models
- Effectively reduces 2-hydroxyglutarate
- Remodels epigenetic state of IDH2-mutant cells
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?